You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Aminomethyl benzamides as novel anti Ebola agents

    SBC: Chicago Biosolutions, Inc.            Topic: NIAID

    Ebola EBOV and Marburg MARV viruses belong to the family Filoviridae and can cause fatal hemorrhagic fevers characterized by widespread tissue destruction with an incubation period of days Because of the safety concerns these viruses are designated as the biosafety level agents Currently there is no effective vaccine or therapeutic treatment against filoviral infection and pathogenes ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  2. Developing a novel adjuvant system for therapeutic vaccines against lung cancer

    SBC: FasCure Therapeutics LLC            Topic: 102

    DESCRIPTION provided by applicant Therapeutics is focused on the development of adjuvant systems with desired immune activities for targeted indications The Companyandapos s immune stimulatory adjuvant platform builds on combinatorial use of immune agonists with distinct immune targets and mechanisms of action for the generation of therapeutic immune responses Critical to this platform techno ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  3. Aminopiperidines as novel anti influenza agents

    SBC: Chicago Biosolutions, Inc.            Topic: NIAID

    Influenza A viruses belong to the orthomyxoviridae family with a negative sense segmented RNA genome which can cause seasonal or pandemic flu with high morbidity and significant mortality Vaccination is the most prevalent prophylactic means for controlling influenza infections However an effective vaccine usually takes at least months to develop for the circulating strains Furthermore vac ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  4. Technology for Synthesis of Chemically Diverse RNAs

    SBC: BIOLYTIC LAB PERFORMANCE, INC.            Topic: 300

    Summary RNA synthesis technologies have become critical in basic biomedical research and in development of RNA based sensors diagnostics and therapeutics Currently RNAs are synthesized by either solid phase phosphoramidite chemistry or by transcription in solution with phage encoded RNA polymerases The structural diversity of chemically synthesized RNAs is limited by the availa ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  5. An epitope focused nanoparticle vaccine for MRSA and biodefense

    SBC: VLP BIOTECH, INC.            Topic: NIAID

    DESCRIPTION provided by applicant Overall Staphylococcus aureus is a gram positive bacteria which possesses a multitude of virulence factors It is a frequent and severe pathogen in hospitals and of increasing concern in the community where it results in severe skin infections pneumonia bacterial endocarditis and sepsis A significant proportion of these infections are the result of methici ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  6. The Allogeneic Heart Stem Cell Trial in Hypoplastic Left Heart Syndrome Patients

    SBC: CAPRICOR, INC.            Topic: NHLBI

    DESCRIPTION provided by applicant One of the most complex forms of congenital heart disease hypoplastic left heart syndrome HLHS affects an average of in every newborns with a mortality rate of up to percent during the first year of life The overall goal f our research is to develop safe and effective ways to improve short term and long term survival rates in babies born with HL ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  7. Mitochondrial TAT-DNA repair proteins for treatment of insulin resistance

    SBC: EXSCIEN CORPORATION            Topic: NIDDK

    DESCRIPTION provided by applicant Insulin resistance IR also known as metabolic syndrome is tied to obesity and is associated with numerous modern health problems including the growing problems of type diabetes and cardiovascular disease The growing health economic and social burdens of these conditions calls for the need to develop drug treatments for IR We know from multiple lines of ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  8. An Agent-Based Modeling Platform for Environmental Biotechnology

    SBC: MICROVI BIOTECH, INC.            Topic: NIEHS

    DESCRIPTION provided by applicant Hazardous compounds in waters and soils are subject to a complex dynamic web of interactions among physical chemical and biological constituents in the natural environment Computational modeling has been proven indispensable to hazardous substances remediation particularly integrated modeling of pollutant hydrogeological fate and transport For the first t ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  9. A simple and effective diagnostic test for gastrointestinal bleeding to improve patient outcomes

    SBC: CUMBERLAND PHARMACEUTICALS, INC.            Topic: 300

    DESCRIPTION provided by applicant Problem Lower gastrointestinal bleeding is a significant medical problem in the United States accounting for more than hospital admissions and tens of billions of dollars of healthcare spending annually It is common for bleeding from a single site to stop and restart multiple times The three modalities now used to diagnose and locate gastrointestina ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  10. Development of a kit for characterization of cellular energetics in single cells in cell and tissue cultures based on the measurement of the absolute magnitude of the mitochondrial membrane potential

    SBC: Gerencser, Akos            Topic: R41

    DESCRIPTION provided by applicant Altered cellular energetics contributes to human disease in general physiological aging and chronic diseases in particular including cancer neurodegeneration ischemic heart disease and type diabetes Pathological changes affecting the individual may arise only in specific cells of a tissue and potentially in a heterogeneous manner To advance basic resea ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government